Stock Market Reviews

ADAG (Adagene Inc.) News

Get the latest news, insights, and market updates on ADAG (Adagene Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• AC Immune And 2 Other Promising Penny Stocks
  As the U.S. stock market shows signs of strength with major indices on track for weekly and monthly gains, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, though often overlooked due to their historical connotations, represent an intriguing segment of the market by highlighting smaller or less-established companies that can offer substantial value. By focusing on those with robust financials and clear growth potential, investors may...
  Oct 31, 2025 - $ADAG
• CD47 Inhibitors Drug Market & Clinical Trials Insight 2026, Featuring Adagene, Akeso, ALX Oncology, EpicentRx, ImmuneOncia, ImmuneOnco Biopharma, Phanes Therapeutics, Virtuoso Therapeutics, and More
  The CD47-targeted therapy market is poised for growth due to its potential in treating resistant cancers. With over 80 drugs in trials, innovations like bispecific antibodies, combination therapies, and personalized treatment strategies are key opportunities, underpinned by significant corporate R&D investments.Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "CD47 Inhibitors Drug Market Opportunity, Clinical Application by Indications & Clinical Trials Insight 2026" report has been added to Resear
  Oct 1, 2025 - $ADAG
• All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
  Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Sep 30, 2025 - $ADAG
• Are Medical Stocks Lagging Adagene (ADAG) This Year?
  Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
  Sep 25, 2025 - $ADAG
• Could Access to SAFEbody Technology Shift Exelixis (EXEL) Pipeline Strategy in Oncology?
  On September 16, 2025, Adagene Inc. announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene's SAFEbody technology platform to generate a masked monoclonal antibody for development as an antibody-drug conjugate targeting solid tumors. This updated partnership could open new avenues for pipeline growth at Exelixis by enabling the creation of next-generation antibody-drug conjugates with milestone and royalty implications for...
  Sep 18, 2025 - $ADAG
• Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
  SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to rec
  Sep 16, 2025 - $ADAG
• Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
  Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
  Sep 8, 2025 - $ADAG
• Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
  SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year’s CSCO Meeting, taking place September 10-14 in Jinan, China. Harnessing the Power of Masked CTLA-4 Blockade: Updated ADG126-P001 Phase 1b/2Results of ADG126 + Pembrolizumab in Advanced MSS CRC Presenter:
  Sep 5, 2025 - $ADAG
• Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
  SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor. “Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, an
  Sep 3, 2025 - $ADAG
• Adagene to Participate in Two Investor Conferences in September
  SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York. H.C. Wainwright 27th Annual Global Investment Conference Fireside Ch
  Aug 26, 2025 - $ADAG